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Abstract Nonadherence to prescribed medication is a
common barrier to effective treatment, and current options
to determine adherence are limited. This study describes
development of an aggregate adherence measure based on
population pharmacokinetics (PK), and its comparison to a
subjective questionnaire, the Morisky 8-item medication
adherence scale (MMAS8), in a trial of psychiatric patients
on stable doses of oral aripiprazole. A comprehensive
model was first built using plasma drug concentration data
from 24 clinical studies comprising 448 patients with over
13,500 observations. Application of this model to inde-
pendent patient profiles for a given drug-dosing regimen
were used to generate the primary aggregate adherence
metric, a ratio of observed versus expected plasma expo-
sures at steady-state. Although the metric is capable of
comparing relative adherence across groups, simulations
showed that the metric is not sufficiently sensitive as an
individual diagnostic in all cases. There were no trends
observed between results from calculated aggregate ad-
herence metrics and total scores from MMAS8 in a single-
visit clinical trial of 47 patients with bipolar 1 disorder or
schizophrenia who were on stable doses of aripiprazole,
although a strong association was observed for one
MMAS8 question. The range of the metric calculated for
patients was between 0.16 and 3.15. The described
approach of a novel ‘‘reverse’’ application of population
PK to quantify relative adherence with an aggregate mea-
sure may be influential for both clinical and pharmaco-
metric communities.
Keywords Aggregate adherence metric  Population
pharmacokinetics  Steady-state plasma drug
concentrations  Simulation  Aripiprazole
Introduction
There is currently great interest in the pharmaceutical and
clinical literature regarding nonadherence to a prescribed
medication [1–5]. Nonadherence is highly prevalent and
remains a major barrier to achieving optimal health out-
comes. In psychotic disorders in particular, a conservative
estimate for nonadherence to prescribed medication is
50 % based on current literature [6]. Additionally, in psy-
chiatry, poor adherence has been associated with symptom
exacerbation [7, 8], relapse [9–12], rehospitalization [13]
and an increased risk of suicide [14–16]. Despite the well-
replicated association between adverse clinical outcomes
and sub-optimal medication adherence, deviation from
medication adherence is difficult to detect and current
methods to determine adherence have substantial limita-
tions. These various methods and their respective limita-
tions have been extensively reviewed elsewhere [17].
Previous efforts handling medication adherence have
focused onmaximizing the accuracy of ingestion records for
analyses [18–20], or describing observed adherence patterns
derived from electronic monitoring systems [21], pharmacy
claims [10], or other methods. In the present work, the goal
was to specifically quantify a measure of relative adherence
across psychiatric patients, and, subsequently, use sparse
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plasma sampling to evaluate whether or not subjective re-
sults from a clinical questionnaire could serve as a surrogate
measure for adherence levels. The Morisky 8-item
medication adherence scale (MMAS8), previously validated
for hypertension patients [13], was used for the subjective
questionnaire, whereas steady-state plasma drug exposure
was selected as the objective measure. Our goal was to
assess correlation between the subjective measure, pur-
ported to detect medication nonadherence, and the objective
measure of relative expected steady-state exposures of
aripiprazole. We wished to assess whether or not subopti-
mal, subjectively measured, adherence behavior would be
associated with lower steady-state plasma drug exposures.
To construct an aggregate adherence metric, a novel ‘re-
verse’ application of population pharmacokinetics (POPPK)
was applied to oral aripiprazole treatment. In a standard
POPPK analysis, doses are administered and recorded, and
plasma sampling over time is used as the basis for the de-
velopment of structural and statistical models. In our ‘re-
verse’ application of POPPK, we started by building a PK
model from historical clinical trial data, then drew plasma
samples from an independent population, and finally used
model outputs to generate a metric of observed versus ex-
pected exposures, driven by average adherence levels. The
analysis was conducted in multiple stages. First, a compre-
hensive population PK model of oral aripiprazole was built
with 24 studies submitted as part of the original new drug
application [22]. The PK model was to be fixed for the pur-
pose of estimating independent patient profiles for given
prescribed dosing regimens, and a simple ratio of observed
versus expected exposures at steady-state was adopted as the
primary metric for comparison. Second, simulations were
conducted to assess the extent to which the calculated metric
might be interpretable at the individual level (as opposed to
the group level). Finally, MMAS8 scores and plasma blood
concentrations of aripiprazole were measured during a
clinical trial and evaluated for comparison using the devel-
oped population PK model. The work stream and results
from this analysis may be influential for the clinical and
pharmacometric communities alike; however, it is the ‘‘re-
verse’’ application of population PK to quantify relative
adherence across groups that is truly unique.
Methods
Population PK model
A POPPK model was developed for oral administration of
aripiprazole using data from 24 clinical studies comprising
448 individuals with over 13,500 observations. A 2-com-
partment model with first-order absorption was found to
best describe the data. Interindividual variability terms
were present on all structural model parameters, and a
proportional residual error model was used. Additionally,
three off-diagonal covariance elements were included be-
tween the volume of the central compartment (VC), the
intercompartmental transfer rate (Q), and the volume of the
peripheral compartment (VP, Fig. 1). The heterogeneous
nature of data collection and inconsistent availability of
covariates across studies inherently manifested in some
modeling limitations. The ultimate intention of the mod-
eling effort was to capture a robust upper-bound of the true
magnitude of variability in the general population for the
structural model parameter values. Therefore, it was pre-
ferred to include all data and accept a larger unexplained
variability on the population parameters, rather than to
select a subset of studies with comprehensive covariate
information and reduce the unexplained variability. Addi-
tionally, it is believed that any improvement in explained
variability would only strengthen the application of the
model application that is discussed in the following sec-
tions. It is assumed that adherence in a clinical trial setting
provides an upper boundary for adherence levels in the real
world (e.g., white-coat phenomenon). It is also assumed
that the presence of any patient reporting error in dosing
times increases the magnitude of observed variability in the
population and (along with the large sample size) is in line
with the objective of providing an upper-bound of the true
magnitude of variability on the parameters.
This article focuses on describing a novel application of
POPPK, and therefore it does not show the full details of
pharmacometric model construction. Nonetheless, brief
model diagnostics and parameter estimates are provided
(Figs. 1, 2), and the final model equations are present in the
supplementary material. Although the highest observed
concentrations tended to be underpredicted (which is not
uncommon for oral medications without intravenous data),
model performance was adequate: visual predictive plots of
observed versus predicted concentrations for the 24 studies
used in building the model are presented as supplementary
material.
Simulations
To assess whether or not the aggregate adherence metric
could be used as an individual diagnostic, in addition to its
primary purpose of comparison across groups, 31 days of
possible dosing events were simulated for 5000 subjects
equally assigned to either an adherent or a nonadherent
group. Subjects in the adherent group were assigned an
80 % probability of taking each scheduled dose, while
patients in the nonadherent group were assigned a 40 %
probability of taking each scheduled dose. Whether a dose
was taken for each subject was decided using independent
Bernoulli calls with success rate consistent with the
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probability of a dosing event given the subject’s adherence
group. Four concentration time points were simulated for
each subject at the end of the 31 days to closely follow the
design of a subsequent clinical study: concentrations were
simulated at 8, 9, 10, and 11 h after the dosing event. As
performance at the individual level is not the primary focus
of this work, this simplified version of adherence presents a
baseline assessment. It is assumed that performance of the
aggregate adherence metric at the individual level would be
reduced with more complicated models of adherence.
Three sets of simulations were conducted to test the
performance of the adherence metric under constant
Fig. 1 Summary for the
population PK model developed
for oral aripiprazole. a Example
of 2-compartment structural
model used to describe
aripiprazole PK. Model
parameters include the first-
order absorption rate constant
(ka), the theoretical volume of
distribution of the central
compartment (VC), the first-
order inter-compartmental
transfer rate (Q), the apparent
clearance of the drug from the
central compartment (CL), and
the theoretical volume of
distribution of the peripheral
compartment (VP). b Final
model parameter estimates with
the following covariate values:
the effect of weight on VP
(WT_VP), CL (WT_CL), and Q
(WT_Q), the effect of age on VP
(AGE_VP), CL (AGE_CL), and
the effect of CYP2D6 poor
metabolizer phenotype on CL
(2D6PM_CL)
Fig. 2 Diagnostic plots for the aripiprazole population PK model
described in Fig. 1a predicted versus observed concentrations. The
blue line represents the line of identity; the red line represents the best
fit for the data and covers only the range of observed data points. b A
plot of the conditional weighted residuals versus time. The overlaid
fitted line is a Loess plot (Color figure online)
J Pharmacokinet Pharmacodyn (2015) 42:263–273 265
123
population parameters (thetas) and different variance con-
ditions: (1) the original model unchanged, (2) the coeffi-
cient of variation (CV) of the apparent clearance term
decreased by half, and (3) all interindividual variability
terms reduced by half, with the relevant covariance terms
reduced by one fourth as Cov(aX,bY) = abCov(X,Y),
where both a and b are equal to 0.5 and X and Y are
separate eta terms. Covariate values for the simulation
dataset were resampled as a block (with replacement) from
the original model-building data set. This was done to
ensure maintenance of the covariance structure expected
from the model.
Using the simulated individual predicted (IPRED) con-
centrations, data sets were generated to estimate individual
parameter values under the assumption that all dosing
events occurred (e.g., 100 % adherent). All model pa-
rameter estimates were fixed with the exception of the in-
terindividual variability term for apparent clearance
(CLapp) and the residual variability. Given the sparse
sampling nature of the profiles, a three-phase sequential
estimation methodology was used (designed to mimic what
would be used for application to the clinical data as ex-
plained below); simulation and estimation control stream
examples are provided as supplementary materials.
Aggregate adherence metric
Upon completion of parameter estimation under the as-
sumption of full adherence, an aggregate adherence metric
was calculated for each subject. Given that all values of
model parameters were fixed to prior estimates (with the
exception of the interindividual variability term on CLapp
and residual error term), it may be asserted that significant
deviations from the expected value—after accounting for
relevant covariate values—are partially attributable to
nonadherence (or over-adherence, i.e., taking too much
medication). The underlying idea is that systematic non-
adherence contributes to deviations in expected drug ex-
posures at steady-state (AUCss), which may be observed
and at least partially quantified. The following metric was










AUCSS,obs is the observed area under the concentration–
time curve at steady-state, based on the Bayesian post hoc
estimate of clearance following the estimation procedure in
NONMEM; AUCSS,exp is derived from the expected value
for clearance given a subject’s covariate values from the
final POPPK model; and s is the dosing interval (24 h). The
final equation for the expected value of clearance in the
model was:
CLexpðL=hrÞ ¼ TVCL ¼ 3:88þWTA  0:0251½
 WT  74:19ð Þ  0:0167  ðAGE  32Þ
 ð1 0:478  2D6PMÞ
ð2Þ
WTA is a binary variable indicating subject’s weight
B115 kg (0 = no, 1 = yes) and 2D6PM is a binary vari-
able indicating subject’s CYP2D6 poor metabolizer phe-
notype (0 = no, 1 = yes). CYP2D6 genotype is a well-
documented covariate for aripiprazole metabolism, and the
remaining covariates in this model are similar to those
found in previous internal reports (data not published). The
final observed CV for the apparent clearance parameter in
the developed model was *39 %, indicating that fully
adherent subjects may generate adherence metrics, as de-
scribed above, between *60 and 140 %. Consequently,
our initial test decision boundary for a nonadherent subject
via the aggregate adherence metric (Eq. 1) was assigned to
\60 % for the simulations testing utility at the individual
level.
Clinical data
The clinical trial conducted for this analysis enrolled 47
patients (31 male) 18–55 years of age, with a current di-
agnosis of bipolar 1 disorder (n = 15) or schizophrenia
(n = 32) (Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition, Text Revision [DSM-IV-TR]
criteria, NCT02050854). Patients had been treated with
oral aripiprazole (10, 15, 20, or 30 mg) for at least 2 weeks
before blood sample collection in order to presume steady-
state. Blood samples for measurement of aripiprazole
plasma concentrations were collected from eligible patients
at visit arrival (hour 0) and at 1, 2, and 3 h post-arrival.
Patients reported the date and time of the last taken dose of
aripiprazole, and completed the MMAS8. Aggregate ad-
herence metric (Eq. 1) values were plotted against total
MMAS8 scores and also against responses to individual
MMAS8 questions. The study was conducted in accor-
dance with International Conference on Harmonisation
Good Clinical Practice guidelines for conducting, record-
ing, and reporting trials, as well as for archiving essential
documents. Consistent with ethical principles for the pro-
tection of human research subjects, no procedures were
performed before study candidates had signed the informed
consent form (ICF). The ICF, protocol, and amendments
for this trial were approved by the institutional review
board or independent ethics committee.
Hardware and software
Data manipulation and data set creation were performed
with user-written code in the Java programming language
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within the NetBeans8.0 integrated development environ-
ment. NONMEM 7.2 was used for PK model building,
simulation, and estimation. Graphics were constructed in
the R statistical programming language (v.3.0.3).
Results
Simulations
Figure 3 shows the relationship between the aggregate
adherence metric and the true underlying adherence at the
individual level from simulations (Fig. 3a), as well as the
misspecification rate of the adherence metric (±SE) at the
individual level, with respect to observed deciles of the true
adherence (Fig. 3b). Using a value of 0.6 as the adherence
decision boundary, the misspecification rate for classifying
a patient as adherent given the current study design was
much lower than for classifying a patient as nonadherent.
‘‘Type I Misspecification’’ indicates that the error is similar
to a type I (alpha) error rate, equivalent to accepting the
null hypothesis when a true difference exists. Likewise, the
‘‘Type II Misspecification’’ is analogous to a type II (beta)
error rate, similar to rejecting the null hypothesis when no
true difference exists. The crossover pattern around 0.55 in
Figs. 3 and 4 represents the switch from nonadherent
Fig. 3 Results from simulations to assess the relationship of the
calculated adherence metric to the true simulated adherence.
a Observed adherence metric, calculated with Eq. 1 versus the true
simulated adherence. The solid reference lines represent the 0.6
adherence decision boundary specified from the original model. A
best-fit linear regression line is overlaid. bMisspecification rate of the
calculated adherence metric with respect to the 0.6 adherence
decision boundary (vertical reference line) within each decile of
adherence. The misspecification rate (open circles) are plotted on the
left boundary of the respective decile group, that is, the
misspecification rate of those patients who were between 20 and
30 % is represented by the open circle at x = 0.2. The error bars
represent the calculated standard error of the proportion. Two separate
lines are plotted for the misspecification of nonadherent patients and
adherent patients. The misspecification error for the nonadherent
patients is[ 0 to the left of the 0.6 reference line, and 0 to the right of
the vertical reference line. Conversely, the misspecification error for
the adherent patient group is[ 0 to the right of the 0.6 reference line,
and 0 to the left of the vertical reference line
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misspecification to adherent misspecification based on the
60 % decision boundary. In the closest deciles near the
decision boundary (50–60 and 60–70 %), where perfor-
mance is expected to be the least sensitive, the difference in
misspecification rate for classifying a patient as adherent
versus nonadherent was approximately twofold (26.1 vs.
57.6 %, respectively). However, the misspecification rate
was below 20 % for patients who were either\30 % ad-
herent or patients who were C80 % adherent.
Misspecification rates from additional simulations
changing the degree of variance in the model parameters
are displayed in Fig. 4. For clarity, the standard errors are
not included as the intent is to show relative effect of al-
tering the variance structure rather than statistical sig-
nificance. For these simulations, the decision boundary was
kept constant at 0.6. When the CV of the clearance pa-
rameter was reduced from *40 to 20 %, there was an
improvement in type I misspecification rate (Fig. 4, dashed
line). When all CV terms were reduced by half (including
covariance terms), there was no apparent improvement in
type I misspecification of nonadherent behavior, but there
was a marked decrease in misspecification of adherent
behavior (Fig. 4, dotted line). Separate comparisons were
made after moving the decision boundary to 0.8 for
Fig. 4 Adherence metric results from simulations to assess the
performance of the adherence metric under different variance
parameter values within the population PK model. Two separate
lines are plotted for each simulation. Misspecification error of patients
in the nonadherent group is presented to the left of the vertical
reference line at x = 0.55 under the ‘‘Type I Misspecification’’
heading, similar to a type I (alpha) error rate, similar to accepting the
null hypothesis when a true difference exists. Likewise, the ‘‘Type II
Misspecification’’ is analogous to a type II (beta) error rate, similar to
rejecting the null hypothesis when no true difference exists. The
misspecification error for the nonadherent patients is[ 0 to the left of
the x = 0.55 reference line, and 0 to the right of the vertical reference
line. Conversely, the misspecification error for the adherent patient
group is[ 0 to the right of the 0.6 reference line, and 0 to the left of
the vertical reference line. The results from the model with all
variance parameters being kept the same are shown as the solid blue
line with open circles; the results of the model with only the CV of the
apparent clearance parameter decreased by half are shown as the
dashed green line with open triangles; and the results of the model
with all parameter CVs decreased by half are shown as the dotted line
with plus symbols (Color figure online)
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simulations with 20 % CV on the clearance parameter (not
shown). Under these conditions, the misspecification rate
around the decision boundary was approximately 50 and
40 % for type I and type II misspecification, respectively.
The increase in type-II misspecification with decreased IIV
and a decision boundary set at (1 - CVCL)/100 suggests
that the true underlying adherence levels are also con-
tributing to the type-II misspecification rates; in other
words, a highly adherent population and a model with low
IIV will still yield a relatively high type-II error rate near
the decision boundary. Provided the decision boundary is
not near the upper limit of adherence for the population, the
results demonstrate that the aggregate adherence metric
may serve as an indicator of adherence or nonadherence in
cases where the observed metric is well outside the ex-
pected variability range for the clearance parameter.
This simplified scenario of adherence simulations
demonstrate that ADHMET values are not appropriate for
individual level diagnostics; however, utility as an indi-
vidual diagnostic is unrelated to its appropriateness as a
measure of relative adherence within groups, and its ability
to serve as the basis for a statistical comparison across
groups under presumed conditions of homogenous
variance.
Clinical PK results
Summary statistics of the aggregate adherence metric for
the 47 patients evaluated in this study are provided in
Table 1. The average (mean) adherence metric calculated
for the clinical data (back calculated from the log-domain)
was 0.679, with a median value of 0.644, and a range of
0.163–3.131. Figure 5 shows the distribution of the loga-
rithm of the adherence metric in the population with the
corresponding QQ-plot comparing the distribution to a
hypothetical normal distribution. Interestingly, there was a
significant difference in ADHMET values across gender in
this study (see supplementary material); however, this re-
lationship is not explored in more detail as the primary
comparison is based solely on questionnaire responses, and
their ability to serve as surrogates for nonadherent behavior
a priori.
Clinical questionnaire correlations
In general, there was no trend observed between the ag-
gregate adherence metric and the observed total score on
the MMAS8 (Fig. 6). However, upon inspection of re-
sponses to individual questions, a strong association was
observed for one question, and one additional question
showed a potential association. Question 4 on the MMAS8
showed a strong relationship in the log-domain and when
tested using a non-parametric Kruskal–Wallis test in the
linear domain (P = 0.011 and P = 0.02, respectively).
Question 6 on the MMAS8 showed a potential association
in the log-domain (P = 0.076). Figure 7 shows box plots
for the distribution of calculated adherence metrics within
each response group for questions 4 and 6; plots for all
individual MMAS8 questions are provided as supplemen-
tary material. Additionally, despite the observed relation-
ship with ADHMET values and gender, there was no
correlation between gender and responses to questions 4 or
6 (see supplementary material).
Discussion
In clinical practice, subjective interpretation of patient re-
sponses is often used as a means for decision-making.
When such responses are intended to identify nonadherent
behavior to a prescribed medication regiment, there is little
evidence as to whether or not these responses will correlate
with differences in objective measures of systemic expo-
sure, which is ultimately the goal of treatment. This work
was initiated to assess whether any such correlations exist
between a particular clinical questionnaire designed to
detect nonadherent behavior and expected plasma drug
exposure levels in psychiatric patients on stable doses of
aripiprazole. In other words, would results from a subjec-
tive questionnaire correlate with objective observations of
steady-state plasma drug exposures in a representative
patient population? To address this question, a novel ‘‘re-
verse-engineering’’-based approach to sparse sampling
population PK was applied.
From a pharmacometric standpoint, nonadherence to a
prescribed medication may lead to decreased systemic
exposure. However, nonadherence is bidirectional and can
manifest as higher than intended systemic exposure when
extra doses are taken. The clinical consequences and
pharmacometric challenges of unobserved nonadherence
has been discussed at large [1, 16, 18–20, 23, 24]. Despite
this acknowledgment, little widespread utility has been
found from using POPPK modeling as a tool for estimating
Table 1 Summary statistics for aggregate adherence metric calcu-
lated from clinical data
N Mean Median Range
Descriptives in log domain
47 -0.387 -0.44 -1.83–1.148
Descriptives back-calculated to linear domain
47 0.679 0.644 0.163–3.151
Descriptives expressed as percent (%)
– 67.9 64.4 16.2–315.1
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adherence levels. Most efforts to mitigate nonadherence
have focused on surrogate measures of compliance, such as
electronic monitoring or patient journals [18, 19], while
little effort has been made to quantify the degree to which
nonadherence may be expected in a given population a
priori under naturalistic conditions. The approach de-
scribed in the current work provides a pharmacometric
measure enabling the comparison of relative adherence
across groups and, to our knowledge, has not been previ-
ously explored. Such a measure might be used in other
areas during drug development; examples include using the
ADHMET approach to distinguish between groups of re-
sponders and non-responders, or using observed ADHMET
percentiles as a potential stratifier in a hazard function for a
particular outcome.
The goal of establishing relative adherence levels to oral
aripiprazole treatment post-approval allowed utility of the
entire family of PK studies that were conducted during the
approval process of this currently marketed drug. This is a
unique use-case scenario for a pharmacometric analysis,
given that most such analyses are performed to inform the
approval process. We believe this approach offers a new
avenue by which pharmacometricians and clinicians may
collaborate to provide unique solutions throughout the
entire lifespan of a compound. In this case, the lack of
correlation of the aggregate adherence metric with the total
score of the MMAS8 is noteworthy because study coordi-
nators may use such questionnaires to set various inclusion
criteria based on the implied inference of such a score.
Although a formal validation of MMAS8 in psychiatric
patients has not been conducted, the scale has previously
been validated in patients with hypertension [25]. One
possible reason for the lack of correlation of steady-state
plasma drug concentrations with the MMAS8 total scores
is patient bias in responses when answering clinical ques-
tionnaires [26, 27]. However, in the current study, we
found that individual questions were more informative in
certain cases than the overall questionnaire score. It was
observed that MMAS8 question 4 ‘‘When you travel or
leave home, do you sometimes forget to bring along your
[health concern] medication(s)?’’ was a significant indi-
cator (unadjusted P\ 0.05) of the adherence metric in this
data set: Patients who answered ‘‘yes’’ to this question had
lower ADHMET values as a group than those who
Fig. 5 Distribution for
calculated adherence metric
values in the clinical study
population
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Fig. 6 Box plots for the
distribution of calculated
adherence metrics within each
group scoring a particular value
on the MMAS8 with the
corresponding analysis of
variance analysis (ANOVA)
P value testing for a difference
across groups for both the
ordinary and log domains. The
dashed line connects the median
values within each group
Fig. 7 Box plots for the
distribution of calculated
adherence metric within each
response group for questions 4
(left) and 6 (right), respectively.
Group medians are connected
by a dashed line, and the
corresponding t test P values are
displayed for each question.
Question 4 reads ‘‘When you
travel or leave home, do you
sometimes forget to bring along
your [health concern]
medication(s)?’’ Question 6
reads ‘‘When you feel like your
[health concern] is under
control, do you sometimes stop
taking your medication(s)?’’
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answered ‘‘no’’. Although there was no correlation with
total MMAS8 scores during a single visit investigation,
the correlation of those test scores with longer-term be-
havioral tendencies assessed by PK sampling cannot be
addressed by this work and still remains an unexplored
topic. Given that screening, enrollment, and sampling
were completed at the same visit, we believe that we
captured the most accurate reflection of patient behavior
with respect to plasma concentrations and willingness to
answer the clinical questionnaire truthfully; however, it is
also possible that patients may answer questionnaires
more truthfully in a private session with their physician,
leading to stronger correlations with medication exposure
in practice.
A limitation of this method is the a priori need for a rich
and robust data set that may be used for building a POPPK
model capable of representing an upper bound of the true
magnitude of variability associated with the model pa-
rameters. Such a data set may not exist during early clinical
development, which may partially explain previous efforts
to minimize the effect of nonadherence rather than to
quantify it. However, it is possible that an ADHMET ap-
proach may be used after Phase 2a or in late clinical de-
velopment (examples above) provided that adequate PK
sampling had been conducted in earlier phases. It should be
noted that this metric is cumulative and is not representa-
tive of adherence with the exact time of dosing; however,
while the exact time of dosing becomes more critical as the
dosing interval exceeds the terminal half-life of the com-
pound, oral therapies are commonly developed for once-
daily dosing accompanied by appreciable accumulation to
steady-state, where minor deviations in the dosing time
may not drastically affect the average profile. Another
limitation of the work is its partial dependence on observed
PK variability for a given compound, which could be a
potential limiting factor for detecting relationships from a
sample size perspective. Given that the aggregate adher-
ence metric is a convolution of expected (normal) vari-
ability and adherence factors, it is not believed to be
appropriate for indicating individual adherence levels—
this is supported by our simplified simulation example.
Additionally, because this study design dealt only with
sparse sampling and a compound with modest variability in
the clearance parameter (CV * 40 %), sensitivity and
specificity at the individual level may change with a denser
sampling strategy, lower variability in the model as a
whole, or both. However, neither the magnitude of ex-
pected variability in the population, nor the lack of sensi-
tivity at the individual level, are expected to effect the
utility of the aggregate adherence metric for group com-
parisons—only the power to which a difference may be
detected across those groups.
Conclusions
A novel ‘‘reverse’’ approach to POPPK was applied as a
primary endpoint in a clinical study to gauge the ultimate
utility of a clinical questionnaire as a surrogate for
medication exposure at steady-state. No observable rela-
tionship was found between the total score on the ques-
tionnaire (the MMAS8) and observed versus expected
plasma concentrations of aripiprazole. However, because
the clinical setting was a single-visit study of patients who
were on stable doses of aripiprazole, extrapolation of these
results to longer-term settings, or to correlations with re-
sponses provided to a physician in private, are not feasible.
This application of POPPK may address a new type of
clinical problem using pharmacometrics that is distinct
from classic pharmacodynamic modeling.
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